Indian Pharma firms grew faster at 7 percent compared to 4 percent of MNCs in 2022: IQVIA

The relative performance of the Indian Pharma companies grew faster at 7% compared to MNCs which grew at 4% in 2022. Further, the number of new launches have increased by 2% to 3032 in 2022 as compared to 2021.

Amongst Chronic TAs, Respiratory registered robust growth of 11% followed by CNS 10%. Cardiac and Diabetes reflected single digit growth at 7% and 6% respectively, while Uro and Pain also registered double digit growth of 16% and 21% respectively.

Gastro, Pain Acute and Gynae led the growth for Acute TA’s with a growth of 11%, 10% and 15%. Meanwhile, antivirals showed -59% degrowth owing to high base in 2021. Meanwhile, Anti-infectives, Vitamins, Minerals, and Nutrients (VMN) and Derma grew in single digits.

The acute market reflected growth of 5% majorly due to growth from AI, Pain, Respi Acute and GI therapies. An indepth data in the report said;

Anti-Infectives

• MAT growth: Value: 5%; Unit: -1.3%

• Cephalosporins, which contributes ~43% of total AI therapy, grew by 6% growth. Macrolides and Quinolones de-grew in single digit at -3% and -2% respectively.

• Azithromycin contributing to 51% of Macrolides de-grew at -13% because of high growth 32% seen in 2021 due to use in COVID

• High growth seen from Ampicillin/ Amoxycillin 20%

• Carbapenems showed degrowth of -8% majorly due to Meropenem -11% whereas Faropenem grew at 16%

Pain

• MAT growth: Value: 10%; Unit: -0.6%

• Antirheumatic, Nonsteroidal market which contributes to 44% of Pain market reflected growth of 10%

• While Anti-Pyretics amongst largest categories have shown growth of 7% (MAT), muscle relaxants amongst smaller ones has shown growth of 4%

• Paracetamol Oral Solids have reflected degrowth at -6% ; whereas Para Liquids, Inj have shown growth of 20% and 15% resp and also Para+Tramadol comb which grew at 14%

Respiratory (Acute)

• MAT growth: Value: 6%; Unit: -1.5%

• Cough preparations contributing ~52% of total therapy sales have shown growth of 5% due to Levosalbutamol & comb reflecting 27% growth

• Cold Preparations as well as Antihistamines, systemic both grew at 9%

Gastro - Intestinal

• MAT growth: Value: 11%; Unit: 2%

• Antipeptic ulcerants contributing to ~42% have reflected growth of 9%

• Laxatives have reflected growth of 12% respectively

• Pantoprazole+Domperidone and Rabeprazole+Domperidone continue to grow at 12% and 6% respectively.

Driven by growth from Cardiac, Anti-diabetes, Neuro and Respi Chronic therapies displayed growth of 9%. A breakup into the segments shows;

Cardiac

• MAT growth: Value: 7%; Unit: -1.9%

• Statins & Hypotensives both grew 11% . They together contribute 47~% of TA sales

• Other Cardiac therapies viz., Betablockers, ARB have registered single digit growth

• Anticoagulants de-grew by -11% majorly due to Enoxaparin degrowing at -33% which had a growth of 75% in 2021

• However Ticagrelor which contributes to 16% to Anticoagulants reflected growth of 30%

Anti-Diabetes

• MAT growth: Value: 6%; Unit: -0.1%

• Glimepiride + Metformin (Traditional OAD) has shown single digit growth of 6% and -2% Unit growth

• High growth seen from Vildagliptin 14% and Vildagliptin + Metformin 9%

• Sitagliptin and Sitagliptin+Metformin which went off-patent in 2022 reflected degrowth of -11% and -3% resp but showed unit growth of 35% and 23% respectively.

• Insulin market showed single digit growth of 4%

Respiratory (Chronic)

• MAT growth: Value: 11% and Unit: 7%

• The inhalation prep market continued to show good growth of 17% pulling up the overall Chronic Resp market growth

• Montelukast and comb market grew at 15%

• Montelukast + Levocetrizine Solids grew at 9% growth

• Bilastine+Montelukast showed exceptional growth of 48%

Neuro / CNS

• MAT growth: Value: 10%; Unit: 0.2%

• Anti-Depressant and Anti-Epileptics, which together constitute 51% of the TA, grew at 9% and 12%

• Gabapentin + Nortriptylin within Antiepileptics has shown high growth of 24% and Brivaracetam with smaller base showed fastest rate of growth of 116%

Owing to Sitagliptin going off patent, Anti-Diabetes market showed high no of new launches in Sitagliptin and its combination market.

Number of new launches (IPM) Average Value/ IN

NI* definition are brands launched in a period of one year. (i.e., NI for Dec 2022 are brands launched from Jan 2022 to Dec 2022)

Talking about Zonal Dynamics, the report said that south and north zones continue to be highest contributing zones. Metros and Class 1 grew at 7% each and Extra Urban market showed 5% growth :